Antipsychotic drugs and risk of pulmonary embolism

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 42-48

  Allenet, Benoit ^a,b   Schmidlin, Sophie ^a   Genty, Céline ^b   Bosson, Jean Luc ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

Antipsychotics; Pulmonary embolism; Risk factor

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; FEMALE; HIGH RISK POPULATION; HOSPITAL; HOSPITAL PATIENT; HUMAN; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEX DIFFERENCE; UNITED STATES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 84855353288     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2210     Document Type: Article

References (39)

1. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med. 1994; 331(24): 1630-1641.
2. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008; 28(3): 370-372.
3. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007; 146(3): 204-210.
4. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005; 165(22): 2677-2682.
5. Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007; 21(6): 643-650.
6. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16(11): 765-776.
7. Hagg S, Bate A, Stahl M, et al. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf. 2008; 31(8):685-694.
8. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry. 2001; 179: 63-66.
9. Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J. 2004; 68(9): 850-852.
10. Kamijo Y, Soma K, Nagai T, et al. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J. 2003; 67(1): 46-48.
11. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000; 356(9237): 1219-1223.
12. Ihde-Scholl T, Rolli ML, Jefferson JW. Clozapine and pulmonary embolus. Am J Psychiatry. 2001; 158(3): 499-500.
13. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. 2000; 355(9210): 1155-1156.
14. Knudson JF, Kortepeter C, Dubitsky GM, et al. Antipsychotic drugs and venous thromboembolism. Lancet. 2000; 356(9225): 252-253.
15. Maly R, Masopust J, Hosak L, et al. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008; 62(1): 3-8.
16. Axelsson S, Hagg S, Eriksson AC, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007; 34(8): 775-780.
17. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. 2000; 356(9225): 252.
18. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008; 358(8): 771-783.
19. Hauptman PJ, Schnitzler MA, Swindle J, et al. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006; 296(15): 1877-1884.
20. Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4, 300, 966 consecutive patients). Am J Cardiol. 2008; 102(12): 1742-1746.
21. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J clin Psychiatry. 2003; 64(supplement 12): 21-51.
22. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 Suppl): 1-56.
23. Methodology WCCfdS. ATC/DDD Index 2010. WHO Ed, Oslo 10.12.09.
24. White RH, Brickner LA, Scannell KA. ICD-9-CM codes poorly indentified venous thromboembolism during pregnancy. J Clin Epidemiol. 2004; 57(9): 985-988.
25. Casez P, Labarère J, Sevestre MA, et al. ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. J Clin Epidemiol. 2010; 63(7): 790-797.
26. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008; 29(18): 2276-2315.
27. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008; 358(10): 1037-1052.
28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373-383.
29. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11): 1130-1139.
30. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005; 365(9465): 1163-1174.
31. Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005; 95(12): 1525-1526.
32. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv. 2008; 59(5): 547-553.
33. Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv. 2006; 57(12): 1693.
34. Aparasu RR, Bhatara V, Gupta S. U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry. 2005; 17(3): 147-152.
35. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002; 10(5): 280-291.
36. Hagg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009; 8(5): 537-547.
37. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology. 1997; 8(6): 671-677.
38. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209- 1223.
39. Aparasu RR, Jano E, Bhatara V. Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm. 2009; 5(3): 234-241.